

COMPANY OVERVIEW

Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo's lead asset is AVTX-009, an anti-IL-1 β mAb, targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

RECENT NEWS

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Apr 2 2024, 7:00 AM EDT

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 29 2024, 4:01 PM EDT

STOCK OVERVIEW

Symbol	AVTX
Exchange	Nasdaq
Market Cap	16.48m
Last Price	\$15.94
52-Week Range	\$3.9501 - \$1,130.40

04/16/2024 04:00 PM EDT

INVESTOR RELATIONS

Avalo Therapeutics
ir@avalotx.com

ICR Westwicke
Chris Brinzey
Managing Director
T: 339-970-2843
chris.brinzey@westwicke.com

AVALO THERAPEUTICS, INC.

1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.